FGFR1 and atypical teratoid rhabdoid tumor: We compared the antitumor effect of BTZ with that of other targeted drugs, including the aurora kinase A inhibitor alisertib (MLN8237) (in a phase 2 clinical trial for patients with ATRT) (NCT02114229), histone deacetylase inhibitor SAHA (enhances the effect of ionizing radiation on ATRT cells) [23] and multiple kinase inhibitor lenvatinib because of the high expression of FGFR1 and RET mRNA in our PDX models (Supplementary Figure S4).